CTX 110
Alternative Names: Anti-CD19+ CAR-T cells - CRISPR Therapeutics; CTX 101 - CRISPR Therapeutics; CTX110Latest Information Update: 28 Nov 2024
At a glance
- Originator CRISPR Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II B-cell lymphoma; Non-Hodgkin's lymphoma
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for phase-I development in B-cell lymphoma(Second-line therapy or greater) in Australia (IV, Infusion)
- 28 Nov 2024 No recent reports of development identified for phase-I development in B-cell lymphoma(Second-line therapy or greater) in Canada (IV, Infusion)
- 28 Nov 2024 No recent reports of development identified for phase-I development in B-cell lymphoma(Second-line therapy or greater) in Germany (IV, Infusion)